FDA seeks input on requiring blister packs for certain opioid pain medicines

May 31, 2019 - 02:53 PM
FDA-update-generic-drugs

The Food and Drug Administration today published a seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and Mitigation Strategy. The proposal would require that certain solid oral dosage forms of immediate-release opioid analgesics commonly prescribed to treat acute pain be made available in fixed-quantity blister packaging for outpatient dispensing. 鈥淭his could reduce the amount of unused opioid analgesics, thereby reducing opportunities for misuse, abuse, inappropriate access and overdose, and possibly reducing the development of new opioid addiction,鈥 the agency said. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 allows the FDA to require special packaging for opioids and other drugs that pose a risk of abuse or overdose. 

Related News Articles

Headline
FDA approves first-in-class non-opioid painkiller聽
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to鈥
Headline
AHA podcast: Englewood Health's Strategies to Combat Rising Opioid Use in Post-Pandemic America
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,鈥
Headline
AHA podcast: Thinking Outside the Box to Reduce Behavioral Health Stigma and Disparities聽
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to鈥
Headline
'Take Back Day' Oct. 28 to dispose safely of prescription drugs
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and鈥
Headline
Agencies target unapproved pharmaceutical products from India
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from鈥
Headline
AHA sends SUPPORT Act reauthorization recommendations to House committee鈥
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and鈥